Samsung Biologics Signs 19.3 Billion KRW Contract for Contract Manufacturing with Danish Pharmaceutical Company
[Asia Economy Reporter Choi Dae-yeol] Samsung Biologics announced on the 20th that it has signed a contract for contract manufacturing of pharmaceuticals with a Danish pharmaceutical company. The contract amount increased to approximately 19.3 billion KRW from the contract signed last year. The company stated that through additional negotiations, the contract amount could increase to 44.7 billion KRW.
Hot Picks Today
"Why Is the Korean Stock Market Surging?"... Even Italy Is Astonished by the KOSPI Rally
- "Invested 95% in Hynix and Reached 10 Billion Won"... Japanese Investor's Proof Post Goes Viral
- Even with High Oil Price Relief Payment, Additional 300,000 Won Per Person to Be Provided... Applications Open from the 18th in This Region
- "South Korea Shows Similar Trend to Developed Nations"...Obesity Analysis of 232 Million People Worldwide [Reading Science]
- "That Thing Wakes Up Every Night" ... Suspicious Object Covers Rural Village
This content was produced with the assistance of AI translation services.
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
